Gadobutrol
- Generic Name
- Gadobutrol
- Brand Names
- Gadavist, Gadovist
- Drug Type
- Small Molecule
- Chemical Formula
- C18H31GdN4O9
- CAS Number
- 770691-21-9
- Unique Ingredient Identifier
- 1BJ477IO2L
- Background
Intravenous gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. It may help visualize and detect vascular abnormalities in the blood brain barrier (BBB) and central nervous system (CNS).
...
- Indication
Gadobutrol is indicated for use with magnetic resonance imaging for the following diagnostic processes:
- Associated Conditions
- Arterial Occlusive Diseases of the Supra-aortic arteries, Coronary Artery Disease (CAD), Malignant Breast Neoplasm, Renal artery occlusion
- Associated Therapies
- -
Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT03910114
- Locations
- 🇺🇸
Vanderbilt Childeen's Hospital, Nashville, Tennessee, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Dotarem vs Gadobutrol Contrast for Breast MRI
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Massachusetts, Worcester
- Target Recruit Count
- 258
- Registration Number
- NCT03730051
- Locations
- 🇺🇸
UMass Medical School, Worcester, Massachusetts, United States
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
- Conditions
- Interventions
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03404648
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 14
- Registration Number
- NCT02967380
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 9
- Registration Number
- NCT02274246
- Locations
- 🇪🇸
Hospital Clinic of Barcelona, Barcelona, Spain
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
- Conditions
- Interventions
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT02156739
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2017-03-20
- Target Recruit Count
- 23
- Registration Number
- NCT01995240
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2018-06-27
- Target Recruit Count
- 47
- Registration Number
- NCT01989000
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid Holland, Netherlands
🇳🇱Academic Medical Center, Amsterdam, Noord Holland, Netherlands
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 229
- Registration Number
- NCT01613417
- Locations
- 🇺🇸
Holy Name Medical Center, Teaneck, New Jersey, United States
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 189
- Registration Number
- NCT01026389
- Locations
- 🇦🇹
AKH hospital, Wien, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.